Alterity Therapeutics Limited
ATHEHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Alterity Therapeutics Limited (ATHE) is listed under Biotechnology. The company carries a $90.3M market cap, placing it firmly in the micro-cap category. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease.
Market Cap
$90.3M
Beta
-0.03
P/E (TTM)
—
P/E (Fwd)
-4.10
EPS (TTM)
$-0.64
EPS (Fwd)
$-1.22
ROE
-47.0%
ROA
-32.5%
Cash
$49.2M
Total Debt
$98,449
Free CF
-$10.6M
52W Change
-3.5%
Annual Financials
Cash vs Debt
Where ATHE stands vs its 150-day and 200-day moving averages
As of the July 15, 2026 close, ATHE finished 29.64% above its 150-day moving average ($3.88) and 27.99% above its 200-day moving average ($3.93). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ATHE overbought or oversold?
At the July 15, 2026 close, ATHE's RSI(14) was 51.3, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $49.2M in cash comfortably exceeding the $98K debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$10.6M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -47.0% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
With a beta below 0.7, Alterity Therapeutics Limited typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. With cash comfortably exceeding debt, ATHE has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Alterity Therapeutics Limited and its sector.